A 12-week , randomized , double-blind , placebo-controlled trial evaluated efficacy and safety of high - or low-dose eszopiclone ( 1 or 2 mg in children aged 6-11 years , 2 or 3 mg in children ages 12-17 years ) , given every evening , in 486 patients with ADHD-related insomnia .